Margot J. Burnell

1.8k citations

32 papers · 1.1k indexed · h-index 12

Internal Medicine top 2%
Cancer Research top 5%
- Breast Cancer Treatment Studies 9
Emergency Medical Services top 2%
Oncology top 5%
- Cancer Treatment and Pharmacology 10
- Colorectal Cancer Treatments and Studies 7
- HER2/EGFR in Cancer Research 4
- Cancer Risks and Factors 2
Pathology and Forensic Medicine top 10%
Pulmonary and Respiratory Medicine
- Gastric Cancer Management and Outcomes 5
- Advanced Breast Cancer Therapies 4
- Lung Cancer Treatments and Mutations 4

Co-authors: Mark N. Levine Kathleen I. Pritchard Lois E. Shepherd Ted Vandenberg V. Bramwell Sean Dolan Pantelis Andreou Erica Burton
Cited by: Internal Medicine Cancer Research Emergency Medical Services
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (4 papers)Breast Cancer Research and Treatment (3 papers)
Partner nations: Canada United States Australia

In The Last Decade

Margot J. Burnell

30 papers receiving 1.1k citations

Peers

Countries citing papers authored by Margot J. Burnell

Since Specialization

Citations

This map shows the geographic impact of Margot J. Burnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margot J. Burnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margot J. Burnell more than expected).

Fields of papers citing papers by Margot J. Burnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margot J. Burnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margot J. Burnell. The network helps show where Margot J. Burnell may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Margot J. Burnell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Margot J. Burnell Line = papers co-authored together Margot J. Burnell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The CAnadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT): A Multi-Phase Program Overview Current Oncology ·Linda E. Carlson,Jacques Ibert,Muhammand Imran,He-Zhi Liu,Lynda G. Balneaves,Alan Bates,Margot J. Burnell,Harvey Max Chochinov,David R. Cléments,Julie M. Deleemans,Steve McKeown,Jean Mathews,Dou Zeng,J Knyziak,Cláudio N. Soares,Wei Tu,Monnica T. Williams	2025	0
2	Impact of breast density on classification of infrared spectroscopy for breath-based breast cancer screening. Journal of Clinical Oncology ·Farah Naz,Melvin F. Richards,E. Zuber,С. Ю. Черных,Margot J. Burnell,Shesla Muthalib,Vaniclécia Alves de Aguiar,Stephen Graham,Gisia Beydaghyan,A. Kaladji,Ulloa Palominos,Erik Scheme	2023	1
3	Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience Breast Cancer Research and Treatment ·Susan Dent,Mayra Nágila Couto dos Santos,Moira Rushton,Lourdes Lucia Travieso-Parker,Mark N. Levine,Wendy R. Parulekar,善宏遠藤,Margot J. Burnell,Kathleen I. Pritchard,Edwin Deutsch,Lois E. Shepherd	2020	8
4	Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials Annals of Oncology ·Rinat Yerushalmi,Bin Dong,Judith‐Anne W. Chapman,Paul E. Goss,Michaël Pollak,Margot J. Burnell,Mark N. Levine,V. Bramwell,Kathleen I. Pritchard,Timothy J. Whelan,James N. Ingle,Lois E. Shepherd,Wendy R. Parulekar,Lei Han,Keyue Ding,Karen A. Gelmon	2017	21
5	A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial Oncotarget ·Melanie Spears,L Di Renzo,Alister D’Costa,Bingshu E. Chen,Cindy Q. Yao,Paul C. Boutros,Margot J. Burnell,Mark N. Levine,Patti O’Brien,Lois E. Shepherd,John M.S. Bartlett	2016	2
6	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer Breast Cancer Research and Treatment ·Ana Elisa Lohmann,Judy-Anne W. Chapman,Margot J. Burnell,Mark N. Levine,Elena Tsvetkova,Kathleen I. Pritchard,Karen A. Gelmon,Patti O’Brien,Lei Han,Hope S. Rugo,Kathy S. Albain,Edith A. Perez,Theodore A. Vandenberg,Haji Chalchal,Ravinder Sawhney,Lois E. Shepherd,Pamela J. Goodwin	2015	15
7	LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results Annals of Oncology ·Nick Pavlakis,Katrin Marie Sjoquist,M.V. OBLIENKO,Andrew Martin,Alexander E. Kochupalov,Y-J. Bang,Chris J. O’Callaghan,Niall C. Tebbutt,Sun Young Rha,Jes Chauviere Lee,Y. T. Lee,Lara Lipton,Margot J. Burnell,Thierry Alcindor,A. H. Strickland,Licenciada en Pedagogía Infantil,Sonia Yip,John Simes,John Zalcberg,David Goldstein	2015	6
8	TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial British Journal of Cancer ·(unknown),John M.S. Bartlett,Torsten O. Nielsen,Dongxia Gao,Karen A. Gelmon,Soumya Mishra,Jane Starczynski,Lei Han,Margot J. Burnell,Mark N. Levine,Kazuyoshi SARUWATARI,Lois E. Shepherd,Judith‐Anne W. Chapman	2015	4
9	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results. Journal of Clinical Oncology ·Nick Pavlakis,Katrin Marie Sjoquist,M.V. OBLIENKO,Andrew Martin,Yoon‐Koo Kang,Yung‐Jue Bang,Christopher J. O’Callaghan,Niall C. Tebbutt,Sun Young Rha,Jeeyun Lee,Y. Choi,Lara Lipton,Margot J. Burnell,Thierry Alcindor,Andrew Strickland,Mark Wong,Jin Won Kim,John Simes,John Zalcberg,David Goldstein	2015	13
10	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial Breast Cancer Research and Treatment ·Shuzhen Liu,Judy-Anne W. Chapman,Margot J. Burnell,Mark N. Levine,Kathleen I. Pritchard,Timothy J. Whelan,Hope S. Rugo,Kathy S. Albain,Edith A. Perez,Shakeel Virk,Garrett Barry,Dongxia Gao,Patti O’Brien,Lois E. Shepherd,Torsten O. Nielsen,Karen A. Gelmon	2014	37
11	Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). Journal of Clinical Oncology ·Ana Elisa Lohmann,Judy‐Anne W. Chapman,Margot J. Burnell,Mark N. Levine,Elena Tsvetkova,Kathleen I. Pritchard,Karen A. Gelmon,Patti O’Brien,Lei Han,Hope S. Rugo,Kathy S. Albain,Edith A. Perez,Theodore A. Vandenberg,Haji Chalchal,Ravinder Sawhney,Lois E. Shepherd,Pamela J. Goodwin	2014	1
12	Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. Journal of Clinical Oncology ·Guy A. Van Hazel,Dongping Tu,Niall C. Tebbutt,Derek J. Jonker,Timothy Price,Christopher J. O’Callaghan,John Zalcberg,Mark Taylor,A. H. Strickland,Anna Tomiak,Desmond Yip,John Simes,Grégory Gatellier,Matthew Links,Margot J. Burnell,Michael Jefford,Christos S. Karapetis	2011	2
13	Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). Journal of Clinical Oncology ·Wendy R. Parulekar,Judith‐Anne W. Chapman,Samuel Aparício,Yvonne Murray,N. Cukanova,Angelo Di Leo,Bella Kaufman,Christelle Lévy,Alexey Manikhas,Marta Gil-Martín,K. I. Pritchard,Lee S. Schwartzberg,Margot J. Burnell,Susan Dent,Sian Ellard,Katia Tonkin,Timothy J. Whelan,Julie Lemieux,Louise Bordeleau,Karen A. Gelmon	2011	3
14	Choriocarcinoma Arising in a Serous Carcinoma of Ovary: An Example of Histopathology Driving Treatment Journal of Obstetrics and Gynaecology Canada ·Sara Hafezi‐Bakhtiari,Izabella Morava-Protzner,Margot J. Burnell,Edward J. Reardon,Terence J. Colgan	2010	7
15	Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer Journal of Clinical Oncology ·Margot J. Burnell,Mark N. Levine,Judith‐Anne W. Chapman,Vivien Bramwell,Karen A. Gelmon,Barbara Walley,Ted Vandenberg,Haji Chalchal,Kathy S. Albain,Edith A. Perez,Hope S. Rugo,Kathleen I. Pritchard,Patti O’Brien,Lois E. Shepherd	2009	112
16	A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes Annals of Oncology ·B. Findlay,Katia Tonkin,Michael Crump,B. Norris,Maureen Trudeau,Martin E. Blackstein,Margot J. Burnell,Jamey Skillings,David M. J. S. Bowman,David Walde,Michelle S. Levine,Kathleen I. Pritchard,Michael Palmer,Dongsheng Tu,L. E. Shepherd	2007	8
17	Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer Journal of Clinical Oncology ·Stephen Couban,Michael Goodyear,Margot J. Burnell,Sean Dolan,Parveen Wasi,David Barnes,T. Hepworth,Erica Burton,Pantelis Andreou,David R. Anderson	2005	243
18	Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study Annals of Oncology ·C. Cripps,Margot J. Burnell,Jacques Jolivet,Gerald Batist,W. Lofters,Janet Dancey,José Iglesias,B. Fisher,E. A. Eisenhauer	1999	87
19	Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology ·Mark N. Levine,V. Bramwell,Kathleen I. Pritchard,B. Norris,Lois E. Shepherd,Hakam Abu-Zahra,B. Findlay,David Warr,David M. J. S. Bowman,James D. Myles,Andrew Arnold,Ted Vandenberg,Robert G. MacKenzie,J Robert,J. Ottaway,Margot J. Burnell,Christopher Kwesi O. Williams,فریده جزء کبیری	1998	442
20	Outcome of Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma Referred for Autologous Bone Marrow Transplantation Leukemia & lymphoma ·Joseph Brandwein,Anne M. Smith,G. R. Langley,Margot J. Burnell,Simon Sutcliffe,Yuanyou Xia	1991	6

About Margot J. Burnell

Margot J. Burnell is a scholar working on Oncology, Cancer Research, Internal Medicine, Biological Psychiatry and Emergency Medical Services, having authored 32 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (9 papers), Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (5 papers), Advanced Breast Cancer Therapies (4 papers), HER2/EGFR in Cancer Research (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Cancer Risks and Factors (2 papers). The work is most often cited by research in Internal Medicine (225 citations), Cancer Research (420 citations), Emergency Medical Services (188 citations), Oncology (649 citations) and Pathology and Forensic Medicine (141 citations). Margot J. Burnell has collaborated with scholars based in Canada, United States and Australia. Frequent co-authors include Mark N. Levine, Kathleen I. Pritchard, Lois E. Shepherd, Ted Vandenberg, V. Bramwell, Sean Dolan, Pantelis Andreou, Erica Burton, Stephen Couban and Andrew Arnold. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Breast Cancer Research and Treatment, Cancers and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact